FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade

Zarwa Idrees 1, Ivan Cancarevic 1, Li Huang 2

1. Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals Queens, New York City, USA
2. Endocrinology, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals Queens, New York City, USA

Corresponding author: Zarwa Idrees, zarwaidrees1@gmail.com

Abstract

Obesity is a recently defined illness whose diagnosis and treatment continue to be stigmatized. Currently, due to lifestyle changes brought on by technological advancements and the wide availability and affordability of high-calorie foods, millions of people around the world suffer from obesity and/or its sequelae. Finding adequate prevention and treatment options would therefore lead to massive improvements in the duration and quality of life of affected individuals. In this review, we searched the PubMed database for studies exploring the safety and efficacy of the five medications currently approved by the FDA for the treatment of obesity. We included only studies pertaining to adult patients that have been published between 2012 and 2022. We found evidence that all the drugs analyzed such as orlistat, phentermine/topiramate, naltrexone-bupropion, liraglutide, and semaglutide appear to be effective in inducing weight loss, with the suggestion that semaglutide may have superior efficacy. However, a massive obstacle in developing treatment guidelines remains the lack of prolonged studies monitoring the long-term safety and efficacy of obesity medications. Nevertheless, in patients at risk of complications from obesity, the benefits of losing fat mass may outweigh the potential side effects associated with these medications and clinicians should prescribe whichever of the FDA-approved pharmacotherapy they deem most appropriate for the patient’s specific set of circumstances.

Introduction And Background

Obesity was first termed a disease in 1760 by English physician Malcolm Flemyng [1]. While there is a stigma associated with obesity, if it is seen as a disease instead of a social parameter, the perspective of the general population might change. Overweight individuals are those with a body mass index (BMI) greater than or equal to 25, while obesity is defined as a BMI of 30 or higher [2]. Obesity is a global epidemic that is still on the rise, affecting billions of people worldwide [3]. WHO reports that more than 1 billion people worldwide are obese, putting them at increased risk of worse health outcomes. Obesity has been associated with diabetes mellitus, cardiovascular disease, hypertension, stroke, decreased female fertility, mental health issues, worse outcomes of COVID-19, increased risk of cancer, and ultimately increased mortality [4-6].

The advancements in technology, a more sedentary lifestyle, along with increased access to high-calorie foods, have become the fundamental cause of the increased prevalence of obesity [7]. Genetic factors also play an important role. Thus, the approach toward obesity is also multifactorial including lifestyle modification, pharmacotherapy, and bariatric surgery. Pharmacotherapy can additionally act as a bridge between lifestyle modification and bariatric surgery.

Obesity and excess weight are preventable and, to an extent, treatable. Clinically significant weight loss is defined as at least a 5% reduction of weight from baseline over a period of three months [8]. Pharmacotherapy should be considered in addition to lifestyle modification in those with a BMI of more than 30 or BMI of 27-30 with at least one weight-related complication (for example Diabetes Mellitus, hypertension, dyslipidemia, coronary artery disease, stroke) according to studies and recommendations by the Endocrine Society [9-10]. Adequate prevention and management could save millions of lives and lead to improved quality of life for a very significant percentage of the global population. The FDA has approved five medications for long-term use for weight loss, namely: orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide [10]. We are going to take a closer look at these five medications, including their efficacy and benefits versus risks.

Review

Methods

This is a narrative literature review. PubMed database was searched using the keywords "pharmacotherapy", "weight loss", "FDA-approved", "orlistat", "phentermine-topiramate", "naltrexone-bupropion", "liraglutide", and "semaglutide".
"liraglutide", and "semaglutide". Observational and interventional studies written in English investigating the outcomes of obesity management with any of the aforementioned drugs that were published between 2012 and 2022 were included. Articles pertaining to pediatric or obstetric patients, review articles, case reports, case series, and articles written in languages other than English were excluded.

**FDA-approved medications**

There are currently five FDA-approved medications for the management of obesity [10-12]. A sixth drug, lorcaserin, was approved for weight loss but was later withdrawn, after being in clinical use for eight years, due to concerns of increased risk of cancer [11].

**Orlistat**

Orlistat is a pancreatic lipase and gastric lipase inhibitor that can lead to a decrease in fat absorption by as much as 30% contributing to weight loss [12,13]. Yu et al. found that administration of orlistat in combination with diet or diet and exercise versus diet alone led to a reduction in body mass index, body weight, waist circumference, and levels of total cholesterol and low-density lipoprotein (LDL) cholesterol [14]. Khera et al. found that 44% of the participants taking orlistat achieved 5% weight loss from baseline compared to only 23% of those receiving placebo (Odds ratio (OR) 2.70, 95% credible interval (CrI) 2.34-3.09, surface under the cumulative ranking curve (SUCRA) 0.22) [15]. At the one-year point, excess weight loss with orlistat compared to placebo was 2.6 kg (95% CrI -3.04 to -2.16 kg) [15]. The XENSOR study by Gorgojo-Martinez et al. showed that, over a period of seven months, both orlistat and liraglutide led to a significant reduction in weight (5.3 kg with orlistat vs 7.7 kg with liraglutide), fasting glucose level, systolic blood pressure, LDL cholesterol, and alanine transaminase [16]. Of the participants taking orlistat, 27.4% lost 5% or more of their baseline weight compared to 64.7% with liraglutide [16]. Grabarczyk found that, after 20 weeks of treatment, patients receiving orlistat experienced a 2.1% decrease in weight from baseline, those receiving phentermine-topiramate 4.1%, phentermine alone 3.6%, whereas only 1.6% weight reduction was reported with MOVE! (Veterans Administration (VA)'s weight management program with at least three clinic visits) (P < 0.05) [17].

Orlistat has been shown to be effective for achieving weight loss of 5% or more from baseline. Its beneficial effect on endothelial function also provides cardiovascular benefits [14]. The addition of medications like orlistat, which are FDA-approved and has an established safety profile, is not only helpful for initial weight loss but also its maintenance. It is an oral medication that most commonly causes gastrointestinal adverse effects, including steatorrhea due to impaired fat absorption, which may lead to a deficiency of fat-soluble vitamins and nutrients [18]. Its safety has not been established in the pediatric population under 12 years old and it is contraindicated for pregnant and breastfeeding women [18,19]. Special consideration should be given to patients with thyroid disease, blood coagulation disorders, epilepsy, and HIV, as orlistat interacts with many of anti-epileptics, anti-virals, and medications requiring close monitoring in these patients [18]. An informed decision should be made based on the patient’s preferences and requirements.

**Phentermine-Topiramate**

Phentermine is a sympathomimetic that suppresses appetite by increasing norepinephrine in the central nervous system. Topiramate, a gamma-aminobutyric acid (GABA) receptor agonist, decreases appetite and increases satiety. It is often used for the treatment of epilepsy and migraine headaches [20,21]. The combination of phentermine with topiramate has been approved by FDA for the management of obesity. Khera et al. found that 44% of the participants taking phentermine-topiramate achieved 5% weight loss from baseline; however, participants taking naltrexone–bupropion lost 2.66 ± 5.03% of body weight compared to 3.63 ± 5.7% with phentermine-topiramate (P < 0.0001) [23]. Lei et al. found phentermine-topiramate effective in the reduction of body weight as well as waist circumference, blood pressure, lipid levels, and plasma glucose levels [24]. The dosage affected the efficacy, and a limiting factor was the association of phentermine-topiramate with nervous system side effects [24]. These studies show phentermine-topiramate to be more effective than placebo and other anti-obesity medications but post hoc analysis of the study by Shi et al. established the superiority of semaglutide for weight loss with similar risks of adverse effects [22].
The combination of phentermine-topiramate allows minimal side effects with proven efficacy for weight loss. The side effects that resulted in discontinuation of treatment included blurry vision, headaches, insomnia, paresthesia, irritability, dizziness, anxiety, and depression [23]. This combination is also contraindicated in pregnant women due to teratogenicity. Special attention should be paid when prescribing this medication to the possibility of acute angle-closure glaucoma, teratogenicity in reproductive-age females, and neuropsychiatric symptoms. The studies have been able to establish the efficacy, but data is lacking regarding long-term side effects. In addition to weight loss and a decrease in waist circumference, it has been shown to be associated with a reduction in lipid levels, plasma glucose levels, and blood pressure. The aforementioned studies suggest that the benefits outweigh the risks of adverse effects by causing weight loss and reduction of weight-related complications when used in an appropriate patient population. However, due to the scarcity of information on long-term side effects, a longer prospective observational study would likely help address some of those concerns.

Naltrexone-Bupropion

The combination of naltrexone, an opioid receptor antagonist, and bupropion, a norepinephrine-dopamine reuptake inhibitor, is used for the management of obesity [26]. Khera et al. found that 25% of participants taking placebo had 5% weight loss compared to 55% of those taking naltrexone-bupropion (OR 3.96, 95% CI 3.05-5.11, SUCRA 0.60) [27]. At the one-year point, excess weight loss as compared to placebo was 5.0 kg (95% CI -5.94 to -3.96). Of the five approved medications, according to a recent meta-analysis, naltrexone-bupropion and liraglutide were found to be associated with the highest odds of treatment discontinuation related to adverse events [15]. Shibuya et al. found that participants taking naltrexone-bupropion lost 2.66 ± 5.03% of body weight compared to 3.65 ± 5.7% with phentermine-topiramate (P < 0.0001) making it non-superior to phentermine-topiramate [23].

Discontinuation of treatment related to adverse effects including nausea, vomiting, constipation, dry mouth, and dizziness has been reported [27]. Further limitations include the inability to use naltrexone in patients taking opioid analogs, while bupropion is contraindicated with medications that lower seizure threshold and monoamine oxidase inhibitors. Like other FDA-approved pharmacotherapy, naltrexone-bupropion can be prescribed for the appropriate patient population to benefit from its effects on weight loss and metabolic profile. However, due to its sympathomimetic effects, it should not be used in patients with uncontrolled hypertension. More studies need to be performed to further assess the long-term safety and benefits related to cardiovascular and metabolic health.

Liraglutide

Liraglutide is a subcutaneous GLP-1 agonist, which is used daily for the management of diabetes mellitus type 2 and obesity/weight management [20]. A systematic review and meta-analysis by Khera et al. found that 23% of participants taking placebo had a weight loss of 5% compared to 63% of those taking liraglutide (OR 5.34, 95% CI 4.16-7.78, SUCRA 0.85). At the one-year point, excess weight loss compared with placebo was 5.3 kg (95% CI -0.66 to -4.52 kg). Liraglutide was one of the two drugs associated with the highest odds of discontinuation of treatment related to adverse events [15]. Rubin et al. found that participants taking semaglutide showed a mean weight change of -15.8% compared to -6.4% in those taking liraglutide and -1.9% with pooled placebo (95% CI -12 to -6.8, P < .001). Participants taking semaglutide showed higher odds of achieving weight loss compared with liraglutide: 10% or higher weight loss was achieved in 70.9% of those taking semaglutide vs 25.6% of those taking liraglutide (OR 6.3, 95%CI 3.5 to 11.2, P < .001), 15% or higher in 55.6% vs 12.0% (OR 7.9, 95% CI 4.1 to 15.4, P < .001), 20% or higher in 38.5 % vs 6.0% (OR 8.2, 95%CI 3.5 to 19.1, P < .001). A similar proportion reported gastrointestinal adverse events; 84.1% with semaglutide and 82.7% with liraglutide. Discontinuation of treatment related to adverse events was 13.5% in those taking semaglutide vs 27.6% with liraglutide [28]. A study by Astrup et al. found that in the first year, participants on liraglutide 5.0 mg lost 5.8 kg more weight than those taking placebo (95%CI 3.7 to 8.0) and 5.8 kg more than those taking orlistat (95% CI 1.6-6.0) (P = 0.0001). Participants receiving liraglutide 2.4/3.0 mg for two whole years lost 3.0 kg more than those receiving orlistat (95% CI 1.3-4.7, P < .001). The liraglutide 2.4/3.0 mg group also experienced improvements in blood lipid levels and blood pressure along with a 52% decreased two-year prevalence of prediabetes and a 59% decreased prevalence of metabolic syndrome [29]. Nausea and vomiting were the most frequently reported side effects [29]. Gorgojo-Martínez et al. found liraglutide to be more effective at weight loss as well as obesity-related metabolic and cardiovascular complications than orlistat [16].

Liraglutide is especially beneficial in overweight or obese diabetic patients as it has also been established as an effective therapy for better glycemic control in type 2 diabetes as an adjunct to oral anti-diabetic medications and/or insulin [30]. The pitfall is the route of administration; oral therapy is generally preferred over subcutaneous therapy but with adequate counseling and education regarding self-administration, these concerns can be alleviated. Once-daily dosing in comparison to weekly dosing of semaglutide also creates comparatively more inconvenience. Discontinuation of treatment has been reported as well due to gastrointestinal side effects, thus making it a favorable option for only those who can tolerate it. Many clinicians are now comfortable prescribing liraglutide in overweight diabetic patients, but they seem to be hesitant to use it for obesity without diabetes. Patients can benefit greatly from the weight loss effects of liraglutide, and its use should be promoted in the appropriate patient population.
Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist that is administered subcutaneously once weekly for the management of diabetes mellitus and has been shown to also induce weight loss [31]. Several trials have been conducted to study the effectiveness of this medication to induce weight loss when added to lifestyle modification. The semaglutide treatment effect for people with obesity (STEP) program includes five phase-3 trials to evaluate Semaglutide 2.4 mg once weekly for the degree of weight loss, efficacy, and tolerability [32]. Wadden et al. found that semaglutide was more effective than placebo for weight loss when used as an adjunct to lifestyle modification, the STEPS randomized clinical trial showed a weight change of -16.0% with semaglutide vs -5.7% with placebo (95%CI -12.0 to -8.6, P < .001) [31]. The STEP4 randomized clinical trial showed weight change with subcutaneous semaglutide was -7.9% as compared to -6.9% with placebo (95%CI -16.0 to -15.5, P < .001) [33]. Improvement was also shown with semaglutide vs placebo in waist circumference -9.7 cm (95% CI -10.9 to -8.5 cm, P < .001), systolic blood pressure -3.9 mmHg (95%CI -5.8 to -2.0 mmHg, P < .001), and physical functioning score SF-36 2.5 (95% CI 1.6 to 3.3, P < .001). Rubino et al. found semaglutide to be more effective than liraglutide for weight loss, participants taking semaglutide showed a mean weight change of -15.8% as compared to -6.4% in those taking liraglutide (95%CI -12 to -6.8, P < .001) [28]. Gastrointestinal side effects were reported with semaglutide and discontinuation of treatment due to side effects was reported to be higher than with placebo in one trial (3.4% with semaglutide vs 0% with placebo) [31]. Another trial reported a similar proportion of participants discontinuing treatment due to adverse events (2.4% with semaglutide vs 2.3% with placebo) [33].

Semaglutide has been emerging as a promising pharmacotherapy for weight management when combined with lifestyle modifications. Studies have shown it to be significantly more effective for achieving and maintaining weight loss than placebo and liraglutide. The downside is the subcutaneous route of administration which might be inconvenient for some patients, although weekly dosing makes it a bit more convenient than daily subcutaneous dosing of liraglutide. Some patients have not been able to tolerate it. For those who can tolerate semaglutide, it can be added to behavioral therapy and diet modification for achieving and maintaining significant weight loss in the obese/overweight population. The possible superiority of semaglutide with a similar risk of adverse events makes it an excellent choice of drug for the management of obesity in the patient population willing to take subcutaneous medication [22].

Table 1 summarizes the relevant clinical studies that evaluated different pharmacological treatments for obesity.

| Authors | Number of patients | Randomization | Length of study | Summary of findings |
|---------|--------------------|---------------|-----------------|---------------------|
| Yu et al., 2013 [14] | 67 | Three groups, Group 1: Diet alone, Group 2: Diet+orlistat, Group 3: Diet+Orlistat+Exercise | 10 weeks | Orlistat in combination with diet and diet plus exercise vs diet alone: decreased body mass index, body weight, waist circumference, and levels of total cholesterol and LDL cholesterol. 23% of those receiving placebo had 5% weight loss compared to 44% of those taking orlistat (OR 2.70, 95% credible interval (CRI) 2.34-3.09. SUCRA 0.22), 75% of those taking phentermine-topiramate (OR 9.22, 95% CRI 6.63-12.85. SUCRA 0.95), 55% of those taking naltrexone-bupropion (OR 3.96, 95% CRI 3.03-5.11. SUCRA 0.60) and 63% of those taking liraglutide (OR 5.54, 95% CRI 4.16-7.78. SUCRA 0.63). After one year, excess weight loss as compared to placebo was 2.6 kg with orlistat (95% CRI -3.04 to -2.16 kg) 8.8 kg with phentermine-topiramate (95% CRI-10.20 to -7.42 kg), 5.0 kg with naltrexone-bupropion (95% CRI -5.94 to -3.96) and 5.3 kg with liraglutide (95% CRI -6.06 to -4.52 kg). naltrexone-bupropion and liraglutide were found to be associated with the highest odds of treatment discontinuation. |
| Khera et al., 2016 [15] | 29,018 | Comparison of FDA-approved medications (orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide) with placebo | NA | Over seven months, both liraglutide and orlistat led to a reduction of weight (7.7 kg with liraglutide vs 3.3 kg with orlistat), systolic blood pressure, fasting glucose level, LDL cholesterol, and alanine transaminase. 64.7% of participants taking liraglutide lost 5% or more of their baseline weight vs 27.4% with orlistat. Liraglutide also led to lower prediabetes rates compared to orlistat. |
| Gorgojo-Martinez et al., 2019 [16] | 500 | Orlistat group VS liraglutide group | 7 months | Over 20 weeks phentermine-topiramate group had 4.1% decrease in weight from baseline vs 3.6% in phentermine group vs 2.1% in orlistat group vs 1.6% in MOVE! group (VA’s weight management program) [P < 0.05]. 40.3% of participants taking phentermine-topiramate achieved 5% weight loss from baseline. |
| Grabarzyk TR 2018 [17] | 66,035 | Lorcaserin group, phentermine-topiramate group, phentermine group, orlistat group, and MOVE group | 6 months | Over seven months, both liraglutide and orlistat led to a reduction of weight (7.7 kg with liraglutide vs 3.3 kg with orlistat), systolic blood pressure, fasting glucose level, LDL cholesterol, and alanine transaminase. 64.7% of participants taking liraglutide lost 5% or more of their baseline weight vs 27.4% with orlistat. Liraglutide also led to lower prediabetes rates compared to orlistat. |
Phentermine-topiramate showed MD of percentage body weight change -7.97 (95%CI -9.28 to –6.66), GLP-1 agonists showed MD of -5.76 (95%CI -6.30 to -5.21). Discontinuation of treatment related to adverse events was reported for GLP-1 agonists (OR 2.17, 95% CI 1.71 to 2.77). Of the FDA-approved agents, phentermine-topiramate was the least likely to be discontinued due to side effects. Post-hoc analysis established superiority of semaglutide for weight loss with almost similar risks of adverse effects.

Average weight loss with anti-obesity medication was 3.45% of body weight from baseline. Participants taking naltrexone-bupropion lost 2.66 ± 5.03% of body weight as compared to 3.63 ± 5.7% with phentermine-topiramate (P < 0.0001)

participants taking semaglutide had mean weight change of -15.8% vs -6.4% in those taking liraglutide and -1.9% with pooled placebo (95%CI -12 to -6.8, P < .001). Loss of at least 10% body weight: 70.9% of those taking semaglutide vs 25.6% of those taking liraglutide (OR 6.3, 95%CI 3.5 to 11.2, P

Mean body weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo (95% CI -12.0 to -8.6, P < .001). 86.6% lost 5% of body weight with semaglutide vs 27.0% with placebo (P < .001), for 10% body weight: 75.3 % with semaglutide vs 27.0% with placebo (P < .001), for 15% body weight: 55.7% vs 13.2% (P < .001). Gastrointestinal adverse events: 82.8% with semaglutide vs 63.2% with placebo. Discontinuation of treatment due to adverse events: 3.4% with semaglutide, 0% with placebo.

Limitations
This is a narrative review and, therefore, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were not fully followed, and a quality assessment of selected studies was not performed. PubMed was the only database used. Insufficient data regarding long-term effectiveness and risks of side effects was available.

Future directions
Further studies need to be conducted, preferably clinical trials, to yield statistically significant results regarding efficacy as well as adverse events and safety of anti-obesity medications. Currently, no clear guidelines for the pharmacotherapy of obesity exist and such studies could help develop them. Moreover, having clear guidelines would likely help ensure insurance coverage of those medications when obesity is the sole indication.
Conclusions
Medical management should be considered when lifestyle modifications alone are insufficient to maintain weight loss. All five anti-obesity medications approved by FDA, i.e., semaglutide (weekly subcutaneous), liraglutide (daily subcutaneous), phentermine-topiramate (oral), orlistat (oral), and naltrexone-bupropion (oral) appear to be effective but data regarding safety profiles, especially long-term safety, is limited. Semaglutide appears to be the most effective of the five drugs, but tolerability and feasibility of subcutaneous administration remain an issue. Although more research into all of the aforementioned medications is needed, current data provide sufficient evidence to support their use. The pharmacotherapy should be individualized based on co-morbidities, gender and age, and patient preference. Clinicians are still hesitant to prescribe these medications due to concerns about adverse events, but this approach should be reconsidered, as obesity should be treated as a disease with an individualized management plan for the individual patient.

Additional Information

Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Flemyng M: A discourse on the nature, causes, and cure of corpulency. Illustrated by a remarkable case, read before the Royal Society, November 1757. L. Davis And C. Reyners, Printers To The Royal Society, Holborn, London; 1757.
2. Apovian CM: Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016, 7:176-85.
3. Caballero B: Humans against obesity: who will win? . Adv Nutr. 2019, 10:S4-9. 10.1093/advances/nmy055
4. World Health Organization: Noncommunicable diseases. (2017). Accessed: 22 June, 2022: http://www.who.int/mediacentre/factsheets/fs355/en/.
5. Silverstein E, de Pergola G, Rosania R, Loverro G: Obesity as disruptor of the female fertility. Reprod Biol Endocrinol. 2018, 16:22. 10.1186/s12958-018-0336-z
6. World Obesity Day 2022 - Accelerating action to stop obesity . (2022). Accessed: May 6, 2022: https://www.who.int/news/item/04-05-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity.
7. World Health Organization: Obesity and overweight. (2022). Accessed: May 6, 2022: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
8. Tsk Yi, Lee SY: Long-term efficacy and safety of anti-obesity treatment: where do we stand? . Curr Obes Rep. 2021, 10:14-50. 10.1007/s13679-020-00422-w
9. Endocrine Society: Pharmacological management of obesity guideline resources . (2016). Accessed: June 9, 2022: https://www.endocrine.org/clinical-practice-guidelines/pharmacological-management-of-obesity.
10. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 . (2021). Accessed: May 6, 2022: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.
11. Lorcaierin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2020.
12. Kwon YJ, Kwon GE, Lee HS, Choi MH, Lee JW : The effect of orlistat on steroid metabolism in obese patients . Front Endocrinol (Lausanne). 2022, 15:82469. 10.3389/fendo.2022.82469
13. Heck AM, Yanovsky JA, Calis KA : Orlistat, a new lipase inhibitor for the management of obesity . Pharmacotherapy. 2000, 20:270-9. 10.1592/phco.20.4.270.34882
14. Yu CC, Li AM, Chan KO, et al. : Orlistat improves endothelial function in obese adolescents: a randomised trial . J Paediatr Child Health. 2015, 49:696-75. 10.1111/jpc.12252
15. Khera R, Murad MH, Chandar AK, et al. : Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis . JAMA. 2016, 315:2424-54. 10.1001/jama.2016.7602
16. Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F : Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study . Int J Clin Pract. 2019, 73:e13399. 10.1111/iadc.13399
17. Grabarcky TR : Observational comparative effectiveness of pharmaceutical treatments for obesity within the veterans health administration . Pharmacotherapy. 2018, 58:19-28. 10.1002/phar.2048
18. Bansal AB, Al Khalili Y : Orlistat. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022.
19. Stang J, Huffman LG : Position of the Academy of Nutrition and Dietetics: obesity, reproduction, and pregnancy outcomes . J Acad Nutr Diet. 2016, 116:657-91. 10.1016/j.jand.2016.01.008
20. Salari N, Jafari S, Darvishi N, Valipour E, Mohammadi M, Mansouri K, Shohaimi S : The best drug supplement for obesity treatment: a systematic review and network meta-analysis . Diabetol Metab Syndr. 2021, 13:110. 10.1186/s13098-021-00733-5
21. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N : Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity . J Hypertens. 2014, 32:1178-88. 10.1097/HJH.0000000000000147
22. Shi Q, Wang Y, Hao Q, et al. : Pharmacotherapy for adults with overweight and obesity: a systematic review
and network meta-analysis of randomised controlled trials. Lancet. 2022, 15:259-69. 10.1016/S0140-6736(21)01640-8
23. Shibuya K, Ali KF, Ji X, et al.: The benefit of short-term weight loss with anti-obesity medications in real-world clinical practice. Endocr Pract. 2019, 25:1022-8. 10.4158/EP-2019-0081
24. Lei XG, Ruan QJ, Lai C, Sun Z, Yang X: Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021, 29:985-94. 10.1002/oby.23152
25. Cosentino G, Conrad AO, Uwaifo GI: Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013, 7:267-78. 10.2147/DDDT.S31443
26. Kim KK: Understanding the mechanism of action and clinical implications of anti-obesity drugs recently approved in Korea. Korean J Fam Med. 2019, 40:63-71. 10.4082/kjfm.19.0015
27. Makowski CT, Gwinn KM, Hurren KM: Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2011, 4:489-94. 10.1159/000355352
28. Rubino DM, Greenway FL, Khalid U, et al.: Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022, 327:158-50. 10.1001/jama.2021.23619
29. Astrup A, Carraro R, Finer N, et al.: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012, 36:845-54. 10.1038/ijo.2011.158
30. Jacobsen LV, Flint A, Olsen AK, Ingwersen SI: Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016, 55:657-72. 10.1007/s40262-015-0545-6
31. Wadden TA, Bailey TS, Billings LK, et al.: Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325:1403-13. 10.1001/jama.2021.1831
32. Kushner RF, Calanna S, Davies M, et al.: Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020, 28:1050-61. 10.1002/oby.22794
33. Rubino D, Abrahamsson N, Davies M, et al.: Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001/jama.2021.3224